Answers are grounded in this paper and cite their sources.
Case report shows secondary pulmonary cryptococcosis complicating gefitinib therapy in lung adenocarcinoma, indicating careful diagnosis is necessary.
In patients with EGFR‐mutant lung adenocarcinoma receiving gefitinib or other EGFR‐TKIs, the development of new pulmonary nodules should not be hastily attributed to disease progression; secondary pulmonary cryptococcosis should be considered in the differential diagnosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: